Immuron (IMRN) Operating Expenses (2016 - 2025)
Immuron (IMRN) posted Operating Expenses of -$5.2 million for Q2 2025, down 7720.61% on a QoQ basis from -$66175.0 in Q3 2024, and up 20.93% year-over-year from -$4.3 million in Q2 2024.
Analysis
Immuron (IMRN) Operating Expenses (2016 - 2025) Analysis & Trends
Immuron has reported Operating Expenses for 10 years, with the latest figure at -$5.2 million in Q2 2025.
- On a quarterly basis, Operating Expenses rose 20.93% year-over-year to -$5.2 million in Q2 2025; TTM through Jun 2025 was -$16.2 million, a 38.81% decrease from a year earlier, with the FY2026 full-year figure at -$6.2 million, down 7620.65% from the prior year.
- Operating Expenses was -$5.2 million for Q2 2025 at Immuron, down from -$66175.0 in the prior quarter.
- The five-year high for Operating Expenses was $249911.6 in Q4 2021, with the low at -$6.5 million in Q2 2024.
- Average Operating Expenses over 5 years is -$2.6 million, with a median of -$2.3 million recorded in 2021.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses plunged 1688.7% in 2023, then gained 20.93% in 2025.
- Over 5 years, Operating Expenses stood at $249911.6 in 2021, then tumbled by 199.22% to -$247958.7 in 2022, then slumped by 1688.7% to -$4.4 million in 2023, then jumped by 98.51% to -$66175.0 in 2024, then sank by 7720.61% to -$5.2 million in 2025.
- The last three Operating Expenses figures came in at -$5.2 million (Q2 2025), -$66175.0 (Q3 2024), and -$6.5 million (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Immuron | 10.28 Mn | 1.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -5.18 Mn |
| Sep 9, 2024 | -66,174.98 |
| Jun 30, 2024 | -6.54 Mn |
| Dec 31, 2023 | -4.44 Mn |
| Jun 30, 2023 | -458,450.49 |
| Dec 31, 2022 | -247,958.71 |
| Dec 31, 2021 | 249,911.60 |
| Jun 30, 2021 | -4.12 Mn |
| Dec 31, 2020 | 343,408.53 |
| Jun 30, 2020 | -3.20 Mn |
| Dec 31, 2019 | 509,279.32 |
| Dec 31, 2018 | 3.05 Mn |
| Dec 31, 2017 | -3.23 Mn |
| Dec 31, 2016 | -2.19 Mn |
| Jun 30, 2016 | -3.69 Mn |